Comparison of detection limits of fourth- and fifth-generation combination HIV antigen-antibody, p24 antigen, and viral load assays on diverse HIV isolates

Journal of Clinical Microbiology

Volumn 56, Issue 8, 2018, Pages

  Stone, Mars ^a,b   Bainbridge, John ^c   Sanchez, Ana M ^c   Keating, Sheila M ^a,b   Pappas, Andrea ^c   Rountree, Wes ^c   Todd, Chris ^c   Bakkour, Sonia ^a,b   Manak, Mark ^d   Peel, Sheila A ^e   Coombs, Robert W ^f   Ramos, Eric M ^f   Shriver, M Kathleen ^g   Contestable, Paul ^h   Nair, Sangeetha Vijaysri ⁱ   Wilson, David H ^j   Stengelin, Martin ^k   Murphy, Gary ^l   Hewlett, Indira ^m   Denny, Thomas N ^c   Busch, Michael P ^a,b   more..

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g BIO RAD LABORATORIES   (United States)

^h Ortho Clinical Diagnostics Inc   (United States)

ⁱ HOLOGIC INC   (United States)

^j Quanterix Inc   (United States)

^k Meso Scale Discovery   (United States)

^l PUBLIC HEALTH ENGLAND   (United Kingdom)

^m CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

more..

Author keywords

Ag detection; Ag Ab combo; Analytic sensitivity; Diagnostics; HIV; Ultrasensitive Ag; Viral load

Indexed keywords

ANTIGEN P24; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN ANTIBODY; UNCLASSIFIED DRUG; GAG PROTEIN;

ARTICLE; BLOOD EXAMINATION; CLADISTICS; CONTROLLED STUDY; GEOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VIRUS ISOLATION; VIRUS LOAD; VIRUS RECOMBINANT; BENCHMARKING; BLOOD; COMPARATIVE STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STANDARDS;

AIDS SERODIAGNOSIS; BENCHMARKING; HIV; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNOASSAY; LIMIT OF DETECTION; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 85050950855     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02045-17     Document Type: Article

References (35)

1. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RCP, Busch MP. 2004. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 86:171–177. https://doi.org/10.1111/j.0042-9007.2004.00416.x.
2. Hollingsworth TD, Anderson RM, Fraser C. 2008. HIV-1 transmission, by stage of infection. J Infect Dis 198:687–693. https://doi.org/10.1086/590501.
3. Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, Nau M, Fletcher JL, Tipsuk S, Vandergeeten C, O’Connell RJ, Pinyakorn S, Michael N, Phanuphak N, Robb ML, RV217 and RV254/SEARCH010 Study Groups. 2016. HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine 11: 68–72. https://doi.org/10.1016/j.ebiom.2016.07.024.
4. Ma Z-M, Stone M, Piatak M, Jr, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ. 2009. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 83:3288 –3297. https://doi.org/10.1128/JVI.02423-08.
5. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo BL, Kleinman SH. 2005. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45:254–264. https://doi.org/10.1111/j.1537-2995.2004.04215.x.
6. Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. 2017. Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure. Clin Infect Dis 64:53–59. https://doi.org/10.1093/cid/ciw666.
7. Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. 1997. The incidence/ window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 11:155–172. https://doi.org/10.1053/tmrv.1997.0110155.
8. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. 2011. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 52(Suppl 1):S17–S22. https://doi.org/10.1016/j.jcv.2011.09.011.
9. Jurriaans S, Back NKT, Wolthers KC. 2011. Ten years of HIV testing with fourth generation assays: the Amsterdam experience. J Clin Virol 52(Suppl 1):S67–S69. https://doi.org/10.1016/j.jcv.2011.09.021.
10. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, Martinson FEA, Cohen MS. 2011. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378:256–268. https://doi.org/10.1016/S0140-6736(11)60842-8.
11. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. 2005. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191:1403–1409. https://doi.org/10.1086/429411.
12. Weber B, Mbargane Fall EH, Berger A, Doerr HW. 1998. Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays. J Clin Microbiol 36:2235–2239.
13. Centers for Disease Control and Prevention. 2017. National HIV testing day and new testing recommendations. MMWR Morb Mortal Wkly Rep 63:537.
14. Delwart E, Slikas E, Stramer SL, Kamel H, Kessler D, Krysztof D, Tobler LH, Carrick DM, Steele W, Todd D, Wright DJ, Kleinman SH, Busch MP, NHLBI-REDS-II Study Group. 2012. Genetic diversity of recently acquired and prevalent HIV, hepatitis B virus, and hepatitis C virus infections in US blood donors. J Infect Dis 205:875– 885. https://doi.org/10.1093/infdis/jir862.
15. Luft LM, Gill MJ, Church DL. 2011. HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int J Infect Dis 15:e661–e670. https://doi.org/10.1016/j.ijid.2011.05.013.
16. Qiu X, Sokoll L, Yip P, Elliott DJ, Dua R, Mohr P, Wang XY, Spencer M, Swanson P, Dawson GJ, Hackett J. 2017. Comparative evaluation of three FDA-approved HIV Ag/Ab combination tests using a genetically diverse HIV panel and diagnostic specimens. J Clin Virol 92:62– 68. https://doi.org/10.1016/j.jcv.2017.05.005.
17. Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. 2011. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25:679–689. https://doi.org/10.1097/QAD.0b013e328342ff93.
18. Antunes R, Figueiredo S, Bartolo I, Pinheiro M, Rosado L, Soares I, Lourenco H, Taveira N. 2003. Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol 41:3361–3367. https://doi.org/10.1128/JCM.41.7.3361-3367.2003.
19. Hora B, Keating SM, Chen Y, Sanchez AM, Sabino E, Hunt G, Ledwaba J, Hackett J, Jr, Swanson P, Hewlett I, Ragupathy V, Vikram Vemula S, Zeng P, Tee K-K, Chow WZ, Ji H, Sandstrom P, Denny TN, Busch MP, Gao F, on behalf of the REDS-III and EQAPOL Programs. 2016. Genetic characterization of a panel of diverse HIV-1 isolates at seven international sites. PLoS One 11:e0157340. https://doi.org/10.1371/journal.pone.0157340.
20. Sanchez AM, Demarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, Stone M, Tobler L, Keating S, Schito M, Busch MP, Gao F, Denny TN. 2014. Development of a contemporary globally diverse HIV viral panel by the EQAPOL Program. J Immunol Methods 409:117–130. https://doi.org/10.1016/j.jim.2014.01.004.
21. Aptima Inc. 2015. HIV-1 Quant Dx assay (package insert). AW-11853 Rev 002. Aptima Inc, San Diego CA.
22. Abbott Molecular Inc. Abbot RealTime HIV-1 assay (package insert). Abbott Molecular Inc, Des Plaines IA. https://www.molecular.abbott/sal/en-us/staticAssets/realtime-hiv-1-package-insert.pdf.
23. Abbott Laboratories. 2009. Architect HIV Ag/Ab combo. Abbott Laboratories,Wiesbaden,Germany.http://www.ilexmedicalcom/files/PDF/ HIVAgAbcombo.pdf.
24. Stengelin M, Roy D, Aghvanyan A, Kenten J, Sigal GB, Glezer EN, Wohl-stradter JN. 2015. HIV p24 immunoassay with the sensitivity of PCR methods. MesoScale Diagnostics, LLC, Rockville, MD.
25. Quanterix Corporation. 2017. Simoa p24. Summary and explanation of the test. Quanterix Corporation, Lexington, MA.
26. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327:307–310. https://doi.org/10.1016/S0140-6736(86)90837-8.
27. Manak MM, Hack HR, Nair SV, Worlock A, Malia JA, Peel SA, Jagodzinski LL. 2016. Evaluation of Hologic Aptima HIV-1 Quant Dx assay on the Panther system on HIV subtypes. J Clin Microbiol 54:2575–2581. https://doi.org/10.1128/JCM.01350-16.
28. Chavez P, Wesolowski L, Patel P, Delaney K, Owen SM. 2011. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J Clin Virol 52(Suppl 1):S51–S55. https://doi.org/10.1016/j.jcv.2011.09.010.
29. Nair SV, Kim HC, Fortunko J, Foote T, Peling T, Tran C, Nugent CT, Joo S, Kang Y, Wilkins B, Lednovich K, Worlock A. 2016. Aptima HIV-1 Quant Dx—a fully automated assay for both diagnosis and quantification of HIV-1. J Clin Virol 77:46–54. https://doi.org/10.1016/j.jcv.2016.02.002.
30. Yek C, Massanella M, Peling T, Lednovich K, Nair SV, Worlock A, Vargas M, Gianella S, Ellis RJ, Strain MC, Busch MP, Nugent CT, Richman DD. 2017. Evaluation of the Aptima HIV-1 Quant Dx assay for HIV-1 RNA quantitation in different biological specimen types. J Clin Microbiol 55:2544–2553. https://doi.org/10.1128/JCM.00425-17.
31. Alere North America. Alere Determine™ HIV-1/2 Ag/Ab combo. Alere North America, Orlando, FL.
32. Stafylis C, Klausner JD. 2017. Evaluation of two 4th generation point-of-care assays for the detection of human immunodeficiency virus infection. PLoS One 12:e0183944. https://doi.org/10.1371/journal.pone.0183944.
33. Livant E, Heaps A, Kelly C, Maharaj R, Samsunder N, Nhlangulela L, Karugaba P, Panchia R, Marrazzo J, Chirenje ZM, Parikh UM, VOICE Study Team. 2017. The fourth generation AlereTM HIV combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. J Clin Virol 94:15–21. https://doi.org/10.1016/j.jcv.2017.06.006.
34. Cohen MS, Gay CL, Busch MP, Hecht FM. 2010. The detection of acute HIV infection. J Infect Dis 202(Suppl 2):S270–S277. https://doi.org/10.1086/655651.
35. Duong YT, Mavengere Y, Patel H, Moore C, Manjengwa J, Sibandze D, Rasberry C, Mlambo C, Li Z, Emel L, Bock N, Moore J, Nkambule R, Justman J, Reed J, Bicego G, Ellenberger DL, Nkengasong JN, Parekh BS. 2014. Poor performance of the Determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a national household survey in Swaziland. J Clin Microbiol 52:3743–3748. https://doi.org/10.1128/JCM.01989-14.